Navigation Links
New Data Show Pfizer's Axitinib Prolonged Overall Survival in,Advanced Pancreatic Cancer When Combined with Standard of Care,Chemotherapy

CHICAGO--(BUSINESS WIRE)--Jun 4, 2007 - Pfizer announced today that axitinib (AG-013736), an investigational oral, selective inhibitor of VEGFR 1, 2,3 (vascular endothelial growth factor receptors 1, 2, 3) combined with gemcitabine showed a trend towards prolonged overall survival (OS) in patients with advanced pancreatic cancer, compared with gemcitabine alone, according to preliminary data from a randomized Phase II trial.

These data were presented at the 43rd American Society of Clinical Oncology (ASCO) Annual Meeting this week, along with results from several other Phase II studies evaluating the efficacy and safety of axitinib in metastatic refractory thyroid, renal cell, non-small cell lung (NSCLC) and breast cancer.

"Pancreatic cancer continues to be one of the most life-threatening and difficult-to-treat solid tumors," said lead study investigator Jean-Philippe Spano, MD, PhD, Hospital La Piti-Salpetriere. "Seeing an agent with this level of activity and tolerability at this stage in development is encouraging news for patients. These findings suggest that axitinib has anti-tumor activity in advanced pancreatic cancer and provide the basis for a Phase III program to further evaluate the potential benefits of this agent in pancreatic cancer patients."

Advanced Pancreatic Cancer

Results from a randomized Phase II study of 103 previously untreated patients with advanced pancreatic cancer demonstrated median overall survival with axitinib in combination with gemcitabine of 6.9 months compared with 5.6 months with gemcitabine alone. Axitinib combined with gemcitabine reduced the risk of death - by 26 percent compared to gemcitabine alone (HR=0.74; CI 0.427 - 1.284).

Advanced Refractory Thyroid Cancer

The anti-tumor effects of single-agent axitinib in advanced refractory thyroid cancer were demonstrated in a single-arm, multi-center Phase II study of 60 patients who were iod ine-refractory, or not suitable candidates for iodine treatment. This showed an objective response rate with axitinib of 30 percent. 72 percent of patients received a clinical benefit, meaning a partial response or stable disease was observed (partial response 30 percent and 42 percent with stable disease greater than or equal to 16 weeks). Treatment duration range was 6-744 days, with 24 patients currently still on treatment.

A global trial of axitinib in advanced refractory thyroid cancer patients, who have become resistant to a commonly used chemotherapy, is ongoing.

Metastatic Breast Cancer

A randomized, double-blind, placebo-controlled Phase II study found that axitinib combined with the chemotherapy docetaxel, demonstrated an acceptable safety profile and anti-tumor activity in the first-line treatment of metastatic breast cancer.

A total of 168 patients were randomized to receive docetaxel plus axitinib (AG) or docetaxel (DOC) plus placebo (PL). The median time to tumor progression (TTP) was 8.2 months in the AG + DOC arm versus 7 months in the DOC + PL arm (P=0.052). The objective response rate (ORR) was 40 percent for AG + DOC arm and 23 percent for DOC + PL arm (P=0.038).

Advanced Renal Cell Carcinoma (RCC)

A multicenter, open-label, Phase II study investigated axitinib in RCC patients with advanced RCC who were resistant to multi-kinase therapy. The study found that axitinib demonstrated anti-tumor activity in advanced RCC.

Of the 62 patients in the study, partial response was observed in 13 patients (21 percent) and 21 patients experienced stable disease (34 percent). Median Progression Free Survival (PFS) was 7.4 months.

Data from an open-label multi-center Phase II study of single-agent axitinib in non-small cell lung cancer were also presented this week.

"Pfizer is committed to delivering new and innovative options to patients living with cancer," said Charles Baum, MD PhD, head of oncolog y development at Pfizer. "These exciting data contribute to an emerging body of research indicating the benefit that oral selective inhibitors of VEGF receptors, like axitinib, may provide to patients. We have plans to further explore axitinib in advanced pancreatic cancer as part of a Phase III program and are continuing to evaluate axitinib across multiple other tumor types."

The most common adverse events in trials of axitinib as a single agent included fatigue, proteinurea, stomatitis/mucositis, hypertension and diarrhea. When studied in combination with myelosuppressive chemotherapies, the most common adverse events included neutropenia, diarrhea, fatigue, stomatitis and hypertension. The complete adverse event profile of axitinib is not yet known.

About Axitinib

Axitinib is an oral, selective inhibitor of VEGFR 1, 2, 3 (vascular endothelial growth factor receptors 1, 2 and 3), which has been shown to induce tumor regression as a single-agent and in combination with chemotherapy. Inhibiting VEGF binding plays a key role in anti-angiogenesis - or blocking blood vessel formation which starves tumors of the blood and nutrients needed for growth.

Axitinib is an investigational agent and has not yet been approved by the U.S. Food and Drug Administration or other global regulatory agencies.

For more information on Pfizer Oncology please visit www.pfizer.com.

DISCLOSURE NOTICE: The information contained in this release is as of June 4, 2007. Pfizer assumes no obligation to update any forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about a product in development, including its potential benefits, that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the uncertainties inherent in research and development; decisions by regulatory authorities regardi ng whether and when to approve any drug applications that may be filed for such product in development as well as their decisions regarding labeling and other matters that could affect its availability or commercial potential; and competitive developments.

A further description of risks and uncertainties can be found in Pfizer's Annual Report on Form 10-K for the fiscal year ended December 31, 2006 and in its reports on Form 10-Q and Form 8-K.

Contact

Pfizer
Vanessa Aristide, 212-733-3784


'"/>




Related medicine technology :

1. 8-Year Long-term Data Demonstrate Prolonged Overall Survival and Length of Disease Remission with Bexxar
2. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
3. Phase IIIb Clinical Data Validate the Overall and Cardiovascular Safety Profile of Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) in Patients with Type 2 Diabetes
4. Anastrozole (Arimidex) Improves Overall Survival in Postmenopausal Women with Early Breast Cancer Receiving Treatment with Tamoxifen
5. Synta Presents Results for STA-4783 in Metastatic Melanoma Showing Improvement in Overall Survival
6. Ontak (denileukin diftitox) Achieves 49.1% Overall Response Rate in Phase III Trial of Cutaneous T-Cell Lymphoma (CTCL)
7. Updated Overall Survival Data From Pivotal Herceptin Adjuvant Studies in HER2-Positive Breast Cancer
8. Nexavar Significantly Extends Overall Survival by 44% in Liver Cancer Patients
9. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
10. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
11. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , Dec. 8, 2016  Diplomat Pharmacy, Inc. (NYSE: DPLO) has ... 2016 Top Workplaces National Standard. To learn ... ... (PRNewsFoto/Diplomat Pharmacy, Inc.) ... an employee survey administered by WorkplaceDynamics, LLC, a research firm specializing ...
(Date:12/8/2016)... 8 de dezembro de 2016  A Mederi Therapeutics Inc . anunciou ... tratamento não cirúrgico para a doença do refluxo gastroesofágico (DRGE). Foto ... ... Live Stretta procedure performed and broadcast during the ... Wuhan Union Hospital ...
(Date:12/8/2016)... DANVILLE, Pa. , Dec. 8, 2016  A ... physicians reports that the use of opioid therapy to ... actually increase the likelihood of more harmful consequences, including ... Davis , M.D., and Zankhana Mehta , M.D., ... current research on chronic opioid therapy. The study was ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... December 08, 2016 , ... The Dan Carlisle Agency, an ... County, is announcing the launch of a charity drive to raise support and ... women and children in Birmingham has grown steadily since the 1980’s, and the ...
(Date:12/8/2016)... Louis, MS (PRWEB) , ... December 08, 2016 , ... ... that serve commercial and residential clients in and around the Hancock County area, is ... for the Hancock County Food Pantry. , The Hancock County Food Pantry has worked ...
(Date:12/7/2016)... ... December 07, 2016 , ... DrugDev again demonstrated its dedication to ... of the early adopters completing EU-U.S. Privacy Shield Certification from the U.S. Department of ... both sides of the Atlantic with a mechanism to comply with EU data protection ...
(Date:12/7/2016)... ... December 07, 2016 , ... Kenall Manufacturing, a leader in sealed healthcare lighting ... MPCNGX is a multi-function, sealed, LED luminaire that meets the needs of everyone in ... it’s needed. , A 2’ x 4’ model features four modes: reading, ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... Smart Device Remote Control through a new partnership with Splashtop Inc. This remote ... its mobile solutions to help businesses maximize their uptime and productivity. , Wavelink ...
Breaking Medicine News(10 mins):